Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus AP induction chemotherapy followed by concurrent chemoradiotherapy and toripalimab maintenance in non-metastatic stage IVB hypopharyngeal cancer
ChiCTR2300074672Phase 2Recruiting
- Sponsor
- Department of Otolaryngology head and Neck Surgery, The Sixth Medical Center, PLA General Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, cisplatin, nedaplatin and paclitaxel in hypopharyngeal cancer, sponsored by Department of Otolaryngology head and Neck Surgery, The Sixth Medical Center, PLA General Hospital. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
toripalimabcisplatinnedaplatinpaclitaxel
03
Conditions
hypopharyngeal cancer
Beyond the preview
Go deeper on ChiCTR2300074672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074672.